Potential FXa inhibitors were developed by a rational design in the first instance, focusing on
a key pharmacophore, present in gold standard drugs Rivaroxaban and Apixaban. The …

Conventional anticoagulant therapies can significantly reduce the risk of stroke and related
complications in patients with atrial fibrillation (AF). Classic oral anticoagulants based on …

Over the last 15 years, low-molecular-weight heparins (LMWHs) have been accepted as the
“gold standard” for pharmaceutical thromboprophylaxis in patients at high risk of venous …

Se seleccionaron seis compuestos con actividad anticancerígena para eYaluar mediante
herramientas informáticas que incorporan inteligencia artificial su potencial como agentes …

For more than 50 years, oral vitamin K antagonists were the choice of anticoagulant for the
long-term treatment and prevention of arterial and venous thromboembolic events. In recent …

Die neuen oralen Antikoagulanzien wie Dabigatran, Rivaroxaban, Apixaban oder Edoxaban
zeigen pharmakokinetische und pharmakodynamische Kenndaten vergleichbar denjenigen …

ABSTRACT Introduction: Direct oral anticoagulants (DOACs) have gained momentum in
recent years in patients requiring anticoagulation for the prevention and management of …

A thrombotic complication is one of the severe clinical outcomes of COVID-19. Various
pathophysiological mechanisms for thrombotic events in COVID-19 have been proposed …

Opinion statement Anticoagulation therapy remains the cornerstone for prevention and
treatment of venous thromboembolism. Currently available parenteral anticoagulants, such …

静脉血栓栓塞疾病诊疗之再认识-[维普官方网站]-www.cqvip.com-维普网  我的维普 购物车 充值
客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议平台 | 学术 …